Your browser doesn't support javascript.
loading
Administration of endothelial progenitor cells accelerates the resolution of arterial thrombus in mice.
Carneiro, Giane D; Sielski, Micheli S; Vieira, Cristiano Pedroso; Costa, Fabio Trindade Maranhão; Werneck, Claudio C; Vicente, Cristina P.
Afiliación
  • Carneiro GD; Structural and Functional Biology Department, State University of Campinas (UNICAMP), São Paulo, Brazil.
  • Sielski MS; Structural and Functional Biology Department, State University of Campinas (UNICAMP), São Paulo, Brazil.
  • Vieira CP; Pharmacology Department, State University of Campinas (UNICAMP), São Paulo, Brazil.
  • Costa FTM; Genetics, Evolution and Bioagents Department, State University of Campinas (UNICAMP), Campinas, Brazil.
  • Werneck CC; Biochemistry and Tissue Biology Department, Institute of Biology, State University of Campinas (UNICAMP), SãoPaulo, Brazil.
  • Vicente CP; Structural and Functional Biology Department, State University of Campinas (UNICAMP), São Paulo, Brazil. Electronic address: cvicente@unicamp.br.
Cytotherapy ; 21(4): 444-459, 2019 04.
Article en En | MEDLINE | ID: mdl-30904331
ABSTRACT

BACKGROUND:

Endothelial progenitor cells (EPCs) are circulating progenitor cells that can play an essential role in vascular remodelling. In this work, we compared the role of two EPCs cultivated with different mediums in the resolution of the arterial thrombus induced by FeCl3 lesion and in vessel re-endothelization in the mouse carotid artery.

METHODS:

Mice mononuclear cells were differentiated into EPCs using Dulbecco's Modified Eagle's Medium (DMEM) and vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and IGF (Insulin Growth Factor) called EPCs--M1) or with EGM2(endothelial growth medium) (media supplemented with growth factors from Lonza called (EPCs-M2) for 30days and characterized using flow cytometry. The animals received three EPC injections post-lesion, and we analyzed thrombosis time, vessel re-endothelization, metalloproteinases activities, eNOS (endothelial Nitric oxide synthase) presence and SDF-1(Stromal Derived Factor- 1) levels in circulation.

RESULTS:

EPC-M1 presented a more immature progenitor profile than EPC-M2 cells. The injection of EPC-M1 prolonged the thrombosis time, and the treatment with the different EPCs increased eNOS expression and MMP2 (Metalloproteinase 2) activity and decreased SDF-1 in plasma. Only EPC-M1 treatment increased both MMP2 and MMP9 and reduced thrombus after 7days. Also, both EPCs decreased platelet aggregation in vitro.

CONCLUSIONS:

EPCs-M1 were more efficient in all of the analyzed assays. EPCsM2 may be a more mature EPC, proliferating less and promoting a less significant matrix remodelling. EPCs can promote vascular remodelling by inhibiting thrombosis and stimulating vascular wall remodelling and the treatment with a more immature progenitor may be more efficient in this process.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trombosis / Células Progenitoras Endoteliales Límite: Animals Idioma: En Revista: Cytotherapy Asunto de la revista: TERAPEUTICA Año: 2019 Tipo del documento: Article País de afiliación: Brasil

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trombosis / Células Progenitoras Endoteliales Límite: Animals Idioma: En Revista: Cytotherapy Asunto de la revista: TERAPEUTICA Año: 2019 Tipo del documento: Article País de afiliación: Brasil